This website represents the collaboration between healthcare professionals interested in breakthrough cancer pain, and 5 pharmaceutical companies that are developing / marketing products for the treatment of breakthrough cancer pain. The website is funded by the 5 pharmaceutical companies, but is maintained by an independent communications company (Eurocom Healthcare Communications Ltd), and the content is overseen by an independent editorial board.

The main objective of the website is to provide a definitive source of information about breakthrough cancer pain for healthcare professionals. The editorial board are entirely responsible for the content of the website, and any opinions expressed on the website are those of the editorial board (and not of the pharmaceutical companies, or of Eurocom Healthcare Communications Ltd). The website will also provide information / resources for patients with breakthrough cancer pain (and their families / carers).

The editorial board are keen to ensure that the website is an up-to-date, evidence-based, clinically-relevant resource for healthcare professionals. Hence, the editorial board would welcome feedback on the current content, suggestions for new content, and relevant submissions.